Get the Stockscreener App
3.39
3.04%
0.10
After Hours:
3.40
0.010
+0.29%
Overview
News
Price History
Option Chain
Financials
Discussions
Forecast
Stock Split
Dividend History
Altimmune Inc stock is traded at $3.39, with a volume of 1.89M.
It is up +3.04% in the last 24 hours and down -3.14% over the past month.
Altimmune Inc is a late clinical-stage biopharmaceutical company developing therapies for patients with serious liver diseases. The Company's key candidate, pemvidutide, is a dual-action therapy targeting both glucagon and GLP-1 receptors in a balanced 1:1 ratio in development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), alcohol use disorder (AUD), and alcohol-associated liver disease (ALD). The company also plans to pursue additional indications for pemvidutide that leverage the differentiated clinical profile of pemvidutide.
See More
Previous Close:
$3.29
Open:
$3.33
24h Volume:
1.89M
Relative Volume:
0.50
Market Cap:
$441.06M
Revenue:
$41,000
Net Income/Loss:
$-88.09M
P/E Ratio:
-3.3386
EPS:
-1.0154
Net Cash Flow:
$-67.55M
1W Performance:
+0.59%
1M Performance:
-3.14%
6M Performance:
-15.25%
1Y Performance:
-25.17%
1-Day Range:
$3.285
$3.42
1-Week Range:
$3.18
$3.44
52-Week Range:
$2.87
$7.73
Altimmune Inc Stock (ALT) Company Profile
Name
Altimmune Inc
Sector
Industry
Phone
(240) 654-1450
Address
910 CLOPPER ROAD, GAITHERSBURG, MD
Compare ALT vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ALT
Altimmune Inc
|
3.39 | 428.05M | 41,000 | -88.09M | -67.55M | -1.0154 |
VRTX
Vertex Pharmaceuticals Inc
|
441.70 | 113.01B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
753.85 | 79.87B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
840.87 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
333.39 | 45.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
319.94 | 34.41B | 5.36B | 287.73M | 924.18M | 2.5229 |
Altimmune Inc Stock (ALT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-18-26 | Initiated | Truist | Buy |
| Jan-28-26 | Initiated | Barclays | Overweight |
| Jul-10-25 | Resumed | Goldman | Sell |
| Feb-28-25 | Initiated | William Blair | Mkt Perform |
| Jan-08-25 | Initiated | Stifel | Buy |
| Nov-12-24 | Initiated | UBS | Buy |
| Apr-29-24 | Downgrade | Guggenheim | Buy → Neutral |
| Jan-24-24 | Initiated | Goldman | Neutral |
| Mar-22-23 | Downgrade | Goldman | Buy → Neutral |
| Dec-01-22 | Initiated | Goldman | Buy |
| Dec-29-21 | Resumed | Jefferies | Buy |
| Jun-02-21 | Initiated | H.C. Wainwright | Buy |
| Feb-11-21 | Initiated | Guggenheim | Buy |
| Dec-14-20 | Initiated | Jefferies | Buy |
| Nov-12-20 | Reiterated | B. Riley Securities | Buy |
| Sep-25-20 | Initiated | B. Riley FBR | Buy |
| Aug-14-20 | Initiated | Evercore ISI | Outperform |
| Jul-31-20 | Initiated | Piper Sandler | Overweight |
| Jul-28-20 | Initiated | JMP Securities | Mkt Outperform |
| Feb-24-20 | Resumed | ROTH Capital | Buy |
| Jul-19-19 | Initiated | ROTH Capital | Buy |
| Oct-09-17 | Initiated | Piper Jaffray | Overweight |
View All
Altimmune Inc Stock (ALT) Latest News
Altimmune launches education drive linking alcohol and liver health - Traders Union
Altimmune Inc Phase 2b Topline 48-Week Data Conference Call Transcript - GuruFocus
ALT (Altimmune) Property, Plant and Equipment : $0.31 Mil (As of Dec. 2025) - GuruFocus
ALT (Altimmune) FCF Margin % : -74,800.00% (As of Dec. 2025) - GuruFocus
ALT Forecast, Price Target & Analyst Ratings | ALTIMMUNE INC (NASDAQ:ALT) - ChartMill
Altimmune: Considering If A Repeat Of The 2025 Run-Up Is On Tap (NASDAQ:ALT) - Seeking Alpha
Altimmune, Inc. (ALT) gains analyst support as pemvidutide advances - MSN
Insider Buying: John Gill Acquires Additional Shares of Altimmune Inc (ALT) - GuruFocus
Altimmune director Gill buys $31k in company stock - Investing.com UK
Altimmune director Gill buys $31k in company stock By Investing.com - Investing.com Australia
Altimmune (ALT) director makes open-market share purchase - Stock Titan
Despite Recent Gains, Altimmune Insiders Are Still Down US$29k - 富途牛牛
Altimmune Inc.’s New Price Target Ignites Investor Interest - timothysykes.com
Altimmune Stock Outlook Brightens as Analysts Raise Price Targets - StocksToTrade
Altimmune’s Stock Target Raised as MASH Program Gains Momentum - timothysykes.com
Gitlab, Altimmune, Cheniere, Pacific Biosciences, Hercules Shock Wall Street - TipRanks
Altimmune’s Price Surge After H.C. Wainwright Strengthens Outlook - StocksToTrade
ALT stock has nearly halved in the past year, so why does Wall Street see almost 500% upside? - MSN
Q3 2025 Altimmune Inc Earnings Call Transcript - GuruFocus
ALT Stock Price, Quote & Chart | ALTIMMUNE INC (NASDAQ:ALT) - ChartMill
Altimmune, Inc. (NASDAQ:ALT) Receives Consensus Rating of "Moderate Buy" from Brokerages - MarketBeat
Lilly gains after FDA approves weight-loss pill, sizing down investor doubts - Sahm
Insider Buying: Gregory Weaver Acquires 10,000 Shares of Altimmu - GuruFocus
Altimmune (ALT) CFO adds 10,000 shares in open-market stock purchase - Stock Titan
Altimmune (NASDAQ: ALT) CEO adds 15,000 shares in open-market buy - Stock Titan
Options Flow: Will Altimmune Inc announce a stock split2026 Market WrapUp & Real-Time Buy Signal Alerts - baoquankhu1.vn
Top 10 stocks under $5 that could triple - MSN
ALT (Altimmune) Common Stock : $0.01 Mil (As of Dec. 2025) - GuruFocus
ALT (Altimmune) Shares Outstanding (Diluted Average) : 105.82 Mil (As of Dec. 2025) - GuruFocus
ALT (Altimmune) 5-Year RORE % : -16.56% (As of Dec. 2025) - GuruFocus
Pullback Watch: Can Altimmune Inc disrupt its industrySell Signal & Low Drawdown Investment Strategies - baoquankhu1.vn
Altimmune Inc. (ALT) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
ALT (Altimmune) FCF Yield % : -17.19 (As of Mar. 27, 2026) - GuruFocus
ALT (Altimmune) Capex-to-Operating-Cash-Flow : 0.00 (As of Dec. 2025) - GuruFocus
ALT Stock Has Nearly Halved In The Past Year, So Why Does Wall Street See Almost 500% Upside? - Stocktwits
Jefferies reiterates Buy on Altimmune stock, keeps $28 target - Investing.com UK
Jefferies reiterates Buy on Altimmune stock, keeps $28 target By Investing.com - Investing.com India
Vanguard subsidiaries disaggregate holdings; Altimmune (NASDAQ: ALT) showing 0 shares - Stock Titan
ALT (Altimmune) EPS without NRI : $-1.01 (TTM As of Dec. 2025) - GuruFocus
Altimmune appoints Luis Sanay as vice president of investor relations to strengthen financial communications - Traders Union
ALT Pemvidutide Uncovered: How It Stands Apart in MASH - Bitget
Altimmune Stock: Balanced Perspective With Major Catalysts Expected in 2026 - Bitget
ALT Stock and the 2026 MASH Race: Dual Agonists vs. New Mechanisms - Yahoo Finance Singapore
Altimmune Stock: Neutral Outlook With Big 2026 Catalysts - TradingView
ALT Pemvidutide Explained: What Makes It Different in MASH - Yahoo Finance
Altimmune a new buy at Truist on pemvidutide promise - MSN
HC Wainwright bullish on Altimmune (ALT) amid growing focus on treatments for metabolic and liver diseases - MSN
H.C. Wainwright Bullish on Altimmune (ALT) Amid Growing Focus on Treatments for Metabolic and Liver Diseases - Insider Monkey
Anti-Aging Protein Research Takes a Step Forward with Cell Cloning - Benzinga
ALT SEC FilingsAltimmune 10-K, 10-Q, 8-K Forms - stocktitan.net
Altimmune outlines 1,800-patient phase III MASH trial and signals cash runway into 2028 as pemvidutide advances - MSN
Altimmune Inc Stock (ALT) Financials Data
Revenue
Net Income
Cash Flow
EPS
Altimmune Inc Stock (ALT) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| WEAVER GREGORY L | Chief Financial Officer |
Apr 01 '26 |
Buy |
3.15 |
10,000 |
31,499 |
38,078 |
| Durso Jerome Benedict | President and CEO |
Apr 01 '26 |
Buy |
3.14 |
15,000 |
47,100 |
47,500 |
| WEAVER GREGORY L | Chief Financial Officer |
Mar 06 '26 |
Buy |
3.54 |
5,000 |
17,700 |
28,078 |
| Durso Jerome Benedict | President and CEO |
Mar 06 '26 |
Buy |
3.54 |
20,000 |
70,790 |
32,500 |
| Roberts M Scot | Chief Scientific Officer |
Feb 02 '26 |
Option Exercise |
0.00 |
7,775 |
0 |
115,153 |
| Roberts M Scot | Chief Scientific Officer |
Jan 30 '26 |
Option Exercise |
0.00 |
9,275 |
0 |
104,670 |
| Garg Vipin K | Director |
Jan 30 '26 |
Option Exercise |
0.00 |
26,775 |
0 |
429,225 |
| Jordt Raymond M | Chief Business Officer |
Jan 27 '26 |
Option Exercise |
0.00 |
15,850 |
0 |
69,765 |
| Garg Vipin K | Director |
Jan 27 '26 |
Option Exercise |
0.00 |
41,200 |
0 |
420,348 |
| Roberts M Scot | Chief Scientific Officer |
Jan 27 '26 |
Option Exercise |
0.00 |
15,850 |
0 |
100,143 |
2.69%
0.25%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):